vinzolidine and Lung-Neoplasms

vinzolidine has been researched along with Lung-Neoplasms* in 2 studies

Other Studies

2 other study(ies) available for vinzolidine and Lung-Neoplasms

Article	Year
Oral vinzolidine as therapy for Kaposi's sarcoma and carcinomas of lung, breast, and colon/rectum. Cancer chemotherapy and pharmacology, 1985, Volume: 14, Issue:1 Vinzolidine, a semisynthetic vinca alkaloid, was studied as oral therapy in 30 patients with Kaposi's sarcoma, non-small cell lung cancer, colorectal cancer, and breast cancer. Substantial variations in morbidity were observed among the patients, some patients receiving doses up to 45 mg/m2 without toxicity while others had severe hematologic toxicity at doses as low as 25 mg/m2. Nausea/vomiting and diarrhea also occurred. Responses were seen in two of 11 patients with Kaposi's sarcoma but not in other patients. Unpredictable severe hematologic toxicity led to early closure of this study. The heterogeneity of patient tolerance may relate to variable oral drug bioavailability, and it is conceivable that vinzolidine could be administered more safely by the IV route. Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Colonic Neoplasms; Female; Humans; Lung Neoplasms; Male; Middle Aged; Rectal Neoplasms; Sarcoma, Kaposi; Vinca Alkaloids	1985
Five-day schedule of vinzolidine, an oral vinca alkaloid, in a variety of tumors. Investigational new drugs, 1984, Volume: 2, Issue:4 This Phase I-II trial evaluated vinzolidine (VZL), a semisynthetic vinblastine derivative administered on a five-day oral schedule every 21 days, with 60% of the total dose on day 1 followed by 10% of the total on each of the following four days. Forty-four patients with advanced malignancies were entered in this study and 34 were evaluable for response. Three patients responded, with complete remissions in patients with adenocarcinoma of the lung (39+ weeks) and adenocarcinoma of the pancreas (20+ weeks) and a minor response in a patient with metastatic carcinoid (6 weeks). Myelosuppression was the dose-limiting toxicity, and was remarkable for its unpredictability among patients and even in the same patient receiving a constant dose of vinzolidine. There was one drug related death associated with myelosuppression. This study was closed because of the erratic myelotoxicity of oral vinzolidine. However, the activity observed with vinzolidine merits future trials, using a parenteral formulation which may have more predictable toxicity. Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Carcinoma, Small Cell; Colonic Neoplasms; Drug Administration Schedule; Drug Evaluation; Female; Humans; Lung Neoplasms; Male; Melanoma; Middle Aged; Pancreatic Neoplasms; Stomach Ulcer; Vinca Alkaloids	1984

Article

Year

Oral vinzolidine as therapy for Kaposi's sarcoma and carcinomas of lung, breast, and colon/rectum.

Cancer chemotherapy and pharmacology, 1985, Volume: 14, Issue:1

Vinzolidine, a semisynthetic vinca alkaloid, was studied as oral therapy in 30 patients with Kaposi's sarcoma, non-small cell lung cancer, colorectal cancer, and breast cancer. Substantial variations in morbidity were observed among the patients, some patients receiving doses up to 45 mg/m2 without toxicity while others had severe hematologic toxicity at doses as low as 25 mg/m2. Nausea/vomiting and diarrhea also occurred. Responses were seen in two of 11 patients with Kaposi's sarcoma but not in other patients. Unpredictable severe hematologic toxicity led to early closure of this study. The heterogeneity of patient tolerance may relate to variable oral drug bioavailability, and it is conceivable that vinzolidine could be administered more safely by the IV route.

Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Colonic Neoplasms; Female; Humans; Lung Neoplasms; Male; Middle Aged; Rectal Neoplasms; Sarcoma, Kaposi; Vinca Alkaloids

1985

Five-day schedule of vinzolidine, an oral vinca alkaloid, in a variety of tumors.

Investigational new drugs, 1984, Volume: 2, Issue:4

This Phase I-II trial evaluated vinzolidine (VZL), a semisynthetic vinblastine derivative administered on a five-day oral schedule every 21 days, with 60% of the total dose on day 1 followed by 10% of the total on each of the following four days. Forty-four patients with advanced malignancies were entered in this study and 34 were evaluable for response. Three patients responded, with complete remissions in patients with adenocarcinoma of the lung (39+ weeks) and adenocarcinoma of the pancreas (20+ weeks) and a minor response in a patient with metastatic carcinoid (6 weeks). Myelosuppression was the dose-limiting toxicity, and was remarkable for its unpredictability among patients and even in the same patient receiving a constant dose of vinzolidine. There was one drug related death associated with myelosuppression. This study was closed because of the erratic myelotoxicity of oral vinzolidine. However, the activity observed with vinzolidine merits future trials, using a parenteral formulation which may have more predictable toxicity.

Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Carcinoma, Small Cell; Colonic Neoplasms; Drug Administration Schedule; Drug Evaluation; Female; Humans; Lung Neoplasms; Male; Melanoma; Middle Aged; Pancreatic Neoplasms; Stomach Ulcer; Vinca Alkaloids

1984